OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments

26.03.2024 - Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, has published its financial results for ...

Related Keywords

United States ,France ,French ,Karine Lignel ,Jan Hoflack ,Oncodesign Services ,Transition Service Agreement ,French Research Tax Credit ,Oncodesign Precision Medicine ,Deep Tech ,Precision Medicine ,Statutory Auditor ,Ordinary General Meeting ,